Esophageal Cancer Awareness Month: The Role of Reflux, Tobacco, and Alcohol

The month, and the group behind it

The Esophageal Cancer Action Network marks April as Esophageal Cancer Awareness Month. Its awareness color is periwinkle, and it runs a Periwinkle Power Day on 17 April.

The reason to pay attention is not the color. It is that this cancer has two forms with different causes, and one of them is largely driven by something people treat as a nuisance: heartburn.

Two cancers in one tube

The esophagus is the muscular tube that carries food from the throat to the stomach. NCI says two cell types account for most cancers there.

Squamous cell carcinoma starts in the flat cells lining the esophagus. NCI lists two risk factors for it: tobacco use and alcohol use.

Adenocarcinoma starts in gland cells. It usually appears in the lower esophagus, near the stomach.

The mix has flipped over sixty years. NCI notes that in the 1960s squamous cell cancers made up more than 90% of esophageal tumors. Adenocarcinoma has risen considerably since. Our overview of esophageal cancer covers both types.

How reflux becomes a risk factor

Adenocarcinoma has a clearer path than most cancers.

Stomach acid rising into the esophagus irritates the lining. Over years, the cells there can change into a type more like the lining of the intestine. That change is called Barrett esophagus. NCI describes chronic reflux as the predominant cause of it.

Barrett esophagus is not cancer. But NCI says its presence raises the risk of developing esophageal adenocarcinoma.

A population-based study from Sweden, cited in NCI's clinical summary, found that the frequency, severity, and duration of reflux symptoms all correlated with higher risk. In other words, it is long-running, severe, daily heartburn that carries the signal — not an occasional bad night.

Why there is no screening program

NCI's screening summary is unusually direct. Based on fair evidence, it says, screening would produce no or minimal decrease in esophageal cancer deaths across the U.S. population.

The harms are better established than the benefit. Endoscopy carries uncommon but serious risks, including perforation, heart and lung events, aspiration, and bleeding that needs a hospital stay. NCI also names a psychological harm: people told they have Barrett esophagus may see themselves as ill, even though their risk of cancer is low.

That is not an argument against seeing a doctor about reflux. It is an argument against scoping everyone who has it.

When to get checked

NCI's symptom list is short and worth knowing by heart. Check with a doctor about:

• Painful or difficult swallowing.
• Weight loss.
• Pain behind the breastbone.
• Hoarseness and cough.
• Indigestion and heartburn.
• A lump under the skin.

One symptom deserves its own line. Difficulty swallowing that is getting worse — food sticking, then softer food sticking, then liquids — is not something to watch and wait on. Book an appointment.

For reflux, the threshold is duration and severity rather than any single episode. Heartburn most days, for years, or heartburn that wakes you at night, or heartburn that needs daily medication to control, is worth raising specifically. Ask whether an endoscopy is warranted in your case.

What treatment involves

Early tumors can sometimes be removed through an endoscope. Most people with locally advanced disease face something bigger.

NCI's clinical summary points to the CROSS trial as the definitive evidence for giving chemotherapy and radiation before surgery. CROSS randomly assigned 366 people with resectable esophageal or junctional cancer to surgery alone, or to five weeks of weekly carboplatin and paclitaxel with radiation, then surgery.

At a median follow-up of 84 months, median overall survival was 24 months with surgery alone and 48.6 months with chemoradiation first. The hazard ratio was 0.68.

Chemoradiation also improved the rate of complete removal, called an R0 resection, from 69% to 92%. Twenty-nine percent of people who had surgery afterward had no cancer left in the specimen at all.

That approach is not universal. NCI notes that for stage I and II disease the picture is less clear: the FFCD 9901 trial found no survival advantage and a higher rate of death after surgery in that group.

What the numbers say

The American Cancer Society estimates about 22,530 new esophageal cancer diagnoses and 16,290 deaths in the United States in 2026, and SEER, NCI's cancer surveillance program, reprints that projection. SEER's own measurement puts the median age at diagnosis at 69.

Only 19% are found while still confined to the esophagus. Thirty-nine percent are found after spread to distant sites.

Five-year relative survival runs 48.6% for localized disease, 29.1% for regional, and 5.3% for distant. Across all stages it is 22.2% for people diagnosed from 2016 through 2022.

NCI puts it plainly in its clinical summary: in most cases esophageal cancer is treatable but rarely curable. Those are registry averages across thousands of people, and they describe no individual.

What to keep in perspective

An awareness month does not lower anyone's risk. Two things actually might.

The first is tobacco and alcohol, which drive the squamous form. NCI names both as risk factors, and both are modifiable. Our guides to quitting smoking and alcohol and cancer risk cover what the evidence supports.

The second is not ignoring swallowing trouble. The stage distribution above is the whole argument: this cancer is usually caught late, and difficulty swallowing is often the symptom that finally sends someone in.

Having reflux does not mean you will get esophageal cancer. Most people with reflux never do, and most people with Barrett esophagus never do either. The point is that a long-running problem is worth a conversation, not silence.

Sources

• Esophageal Cancer Action Network: April is Esophageal Cancer Awareness Month
• NCI PDQ: Esophageal Cancer Treatment (Health Professional Version)
• NCI PDQ: Esophageal Cancer Screening (Health Professional Version)
• NCI: Esophageal Cancer Symptoms
• NCI SEER Cancer Stat Facts: Esophageal Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.